

1 **Caspase-3 dependent peritubular capillary dysfunction is pivotal for**  
2 **transition from acute to chronic kidney disease after acute ischemia-**  
3 **reperfusion injury**

4  
5 Shanshan Lan<sup>1,2,3</sup>, Bing Yang<sup>1,2,3</sup>, Francis Migneault<sup>1,2</sup> Julie Turgeon<sup>1,2</sup>, Maude Bourgault<sup>1</sup>,  
6 Mélanie Dieudé<sup>1,2,3</sup>, Héroïse Cardinal<sup>1,2,3</sup>, Michael J. Hickey<sup>5</sup>, Natacha Patey<sup>1,3,4</sup>, Marie-Josée  
7 Hébert<sup>\*1,2,3</sup>

8  
9 1. Research Centre, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada;

10 2. Canadian Donation Transplant Research Program, Edmonton, Alberta, Canada;

11 3. Université de Montréal, Montreal, Quebec, Canada;

12 4. Department of Pathology, Centre hospitalier universitaire Sainte-Justine, Université de Montréal,  
13 Montreal, Quebec, Canada;

14 5. Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical  
15 Centre, Clayton, Victoria 3168, Australia.

16  
17 Running Head: Central role of PTCs in AKI to CKD transition

18  
19 **Corresponding author:**

20 Dr. Marie-Josée Hébert

21 CRCHUM, Faculty of Medicine, Université de Montréal,

22 900, rue Saint-Denis, Montreal, Quebec, Canada, H2X 0A9

23 Phone: +1- 514 890-8000, poste 25017

24 Fax : +1- 514 412-7624

25 Email: [marie-josée.hebert@umontreal.ca](mailto:marie-josée.hebert@umontreal.ca)

26

27 Supplemental Material Available at :

28 <https://doi.org/10.6084/m9.figshare.14782251>

29 <https://doi.org/10.6084/m9.figshare.13490847>

30 <https://doi.org/10.6084/m9.figshare.13490703>

31

32

### 33 **Abstract**

34 Ischemia-reperfusion injury (IRI) is a major risk factor for chronic renal failure. Caspase-3, an  
35 effector responsible for apoptosis execution, is activated within peritubular capillary (PTC) in the  
36 early stage of IRI-induced acute kidney injury (AKI). Recently, we showed that caspase-3-dependent  
37 microvascular rarefaction plays a key role in fibrosis development after mild renal IRI. Here, we  
38 further characterize the role of caspase-3 in microvascular dysfunction and progressive renal failure  
39 in both mild and severe AKI, by performing unilateral renal artery clamping for 30/60 minutes with  
40 contralateral nephrectomy in wild-type (C57BL/6) or caspase-3<sup>-/-</sup> mice. In both forms of AKI,  
41 caspase-3<sup>-/-</sup> mice showed better long-term outcomes in spite of worse initial tubular injury. After 3  
42 weeks, they showed reduced PTC injury, decreased PTC collagen deposition and  $\alpha$ -SMA  
43 expression, and lower tubular injury scores when compared to wild-type animals. Caspase-3<sup>-/-</sup> mice  
44 with severe IRI also showed better preservation of long-term renal function. Intra-vital imaging and  
45 micro-computed tomography (microCT) revealed preserved PTC permeability and better terminal  
46 capillary density in caspase-3<sup>-/-</sup> mice. Collectively, these results demonstrate the pivotal importance  
47 of caspase-3 in regulating long-term renal function after IRI and establish the predominant role of  
48 PTC dysfunction as a major contributor to progressive renal dysfunction.

49

### 50 **New and Noteworthy**

Our findings demonstrate the pivotal importance of caspase-3 in regulating renal microvascular dysfunction, fibrogenesis, and long-term renal impairment after acute kidney injury (AKI) induced by ischemia-reperfusion injury (IRI). Furthermore, this study establishes the predominant role of peritubular capillary (PTC) integrity as a major contributor to progressive renal dysfunction post-IRI.

51

52

## 53 Introduction

54 Acute kidney injury (AKI) is one of the most powerful predictors of progressive renal failure in both  
55 native and transplanted kidneys (1). More than 20% of hospitalized adults worldwide experience  
56 some level of AKI (2-4) prompted most commonly by ischemia-reperfusion injury (IRI) and sepsis  
57 (5). IRI is an integral component of kidney transplantation and AKI occurs in 20%-50% of  
58 transplantations from deceased donors in the immediate postoperative period (6-8). The severity  
59 and number of AKI episodes in various patient cohorts predicts progressive long-term renal  
60 dysfunction and risk of end-stage renal failure (4, 9-12). Long referred to as acute tubular necrosis,  
61 AKI is classically considered a disease of tubular epithelial cells. Increased cell death of tubular  
62 epithelial cells, in the form of apoptosis and necroptosis, is indeed an important characteristic of AKI  
63 and tends to occur predominantly at the cortico-medullary junction where blood and oxygen supply is  
64 limited (13). However, microvascular injury has emerged in the past decade as a major and  
65 previously underappreciated factor regulating progressive renal dysfunction after AKI (5, 14-16).  
66 Loss of peritubular capillary (PTC) favors chronic hypoxia leading to overexpression of hypoxia-  
67 inducible factor-1  $\alpha$  (HIF-1 $\alpha$ ) and fibrogenic factors which in turn favor myofibroblast differentiation  
68 and fibrosis (5, 15, 17-20). In transplanted kidneys, the magnitude of microvascular involution during  
69 the first 3 months following transplantation is a major negative predictor of long-term renal allograft  
70 function (21). Studies using in vivo imaging and electron microscopy demonstrated a tight  
71 correlation between PTC dysfunction/rarefaction and renal fibrosis in murine models of AKI and in  
72 human kidney biopsy samples (22-24).

73 Caspase-3 is an effector caspase responsible for the induction of apoptosis. Caspase-3 activation is  
74 present within PTC in the early stage of IRI-induced AKI (17, 25). Our group recently showed that  
75 caspase-3 dependent microvascular involution plays a predominant role in regulating the transition  
76 from AKI to fibrosis after mild renal IRI (26). Upon renal artery clamping, caspase-3<sup>-/-</sup> mice show  
77 early increases in tubular epithelial cell injury translating into more severe early renal dysfunction

78 than wild-type controls. Incapacity to mount an apoptotic response in caspase-3 deficient mice  
79 redirects tubular epithelial cell death towards necroptosis, a more severe and inflammatory type of  
80 cell death. Yet, in spite of increased early tubular cell death and acute renal dysfunction, PTC are  
81 largely protected from IRI-induced cell death. Inhibition of PTC apoptosis does not fuel other forms  
82 of regulated cell death but rather prevents microvascular rarefaction and long-term renal fibrosis.  
83 There is no impact of caspase-3 deficiency on long-term renal function. These results confirm a  
84 predominant role for microvascular injury over early epithelial injury as a driver of renal fibrosis after  
85 IRI.

86 Renal fibrosis is classically considered a surrogate marker of progressive renal failure. Yet, recent  
87 data suggest that progressive renal dysfunction after AKI is not always correlated with renal fibrosis  
88 (24). Having identified a predominant role for caspase-3-dependent microvascular injury in renal  
89 fibrogenesis after mild IRI, we now aim at evaluating the impact of caspase-3 on microvascular  
90 function and integrity, fibrogenesis and renal function after severe IRI. In the present study, we  
91 compare early and late microvascular and tubular abnormalities in caspase-3 deficient mice exposed  
92 to mild and severe forms of IRI. Our goal is to assess whether caspase-3 deficiency preserves  
93 microvascular integrity and function even in severe forms of AKI or rather increases PTC injury, as  
94 was the case for renal epithelial cells in mild forms of AKI.

95

## 96 **Materials and Methods**

97

### 98 **Animal and Surgical Procedures**

99 We used 6-8 weeks old female C57BL/6 mice from Charles River Laboratories (Wilmington,  
100 MA,USA). CASP3-deficient (caspase-3<sup>-/-</sup>) mice on a C57BL/6 congenic background, aged 6–8  
101 weeks, were derived from breeding pairs of heterozygous CASP3-deficient (B6.129S1-C3tm1Flv/J)  
102 mice obtained from Jackson Laboratory (stock #006233; Bar Harbor, ME). The generation of these  
103 mice was previously described (26). These homozygote mice were viable, reached adulthood, and

104 showed a variety of hyperplasias and disorganized cell deployment in the brain. All mice were kept  
105 in 12-hour light/dark cycles, with normal food provided ad libitum. IRI by unilateral renal artery  
106 clamping plus contralateral nephrectomy was performed as described previously (26). Detailed  
107 surgical procedures can be found in Supplemental Material. Animals were divided into mild AKI  
108 (IR30m) and severe AKI (IR60m) and were sub-grouped into pre-operation, SHAM, 1 day, 2 days, 7  
109 days, and 21 days post-operation groups. A maximum of 10 mice per sub-group were used. The  
110 number of mice per experiment is described in figure legends. Carprofen was injected  
111 subcutaneously daily until day 3 post-op. Mice with significant body weight loss were also injected  
112 with 0.5 mL saline + 0.3 mL 2,5% dextrose. Mice were euthanized by neck dislocation, after  
113 performing cardiac puncture under 2% isoflurane inhalation at baseline or on days 1, 2, 7, or 21  
114 post-surgery and the left kidney, serum, and urine were collected.

115

#### 116 **Renal Function Biochemical Evaluation**

117 Serum creatinine levels were determined using Vitro CREA slides and Vitro chemistry products  
118 (Vitro 250/350 Chemistry System; Ortho Clinical Diagnostics, Raritan, NJ), as described in our  
119 previous work (26, 27).

120

#### 121 **Renal Histopathological Examination**

##### 122 *Tubular Injury Score*

123 Tubular injury score was evaluated in murine renal tissue stained with haematoxylin and eosin (HE),  
124 as described previously (26). Ten high-power magnification fields (200X) were randomly chosen;  
125 five from the renal cortex and five from the cortico-medullary junction. Based on the percentage of  
126 affected tubules, the tubular injury score was classified as 0-5 (0: normal; 1: mild injury, involvement  
127 of 0%–10%; 2: moderate injury, involvement of 11%–25%; 3: severe injury, involvement of 26%–  
128 49%; 4: high severe injury, involvement of 50%–75%; 5: extensive injury, involvement of 75%). The  
129 criteria for tubular injury involved: brush border loss, tubular dilation, cast formation, tubular necrosis,

130 as well as neutrophil infiltration. All assessments were done by two investigators blinded to  
131 experimental conditions (28).

### 132 *Peritubular Capillary Vascular Congestion*

133 Rouleaux formation, a read-out of peritubular capillary microvascular congestion, was estimated by  
134 counting accumulated erythrocytes inside peritubular capillaries (PTC) on HE-stained slides. Ten  
135 randomly chosen high magnification fields were counted per mouse by two investigators blinded to  
136 experimental conditions.

137

### 138 **Immunohistochemistry**

139 Mice were sacrificed at different time points (baseline, days 1, 2, 7 and 21). Kidneys were collected  
140 and fixed in 10% formalin, embedded in paraffin, and subsequently cut into 4- $\mu$ m slices.  
141 Immunohistochemistry staining was performed on paraffin-embedded tissue as described previously  
142 (26). The antibodies used in this study were mouse endothelial cell antigen (MECA-32; 1:20; 120501;  
143 Biologend, San Diego, CA, USA), HIF-1 $\alpha$  (1:200; ab2185; Abcam, Cambridge, MA, USA),  $\alpha$ -smooth  
144 muscle actin ( $\alpha$ -SMA; 1:200, clone 1A4; Dako, Santa Clara, CA, USA). Stained slides were scanned  
145 (original magnification 200X) using an Olympus VS110 slide scanner and randomly chosen fields  
146 were evaluated. Quantification of MECA-32 staining in PTC were assessed by evaluating the ratio of  
147 positive PTC/ tubule number in five high-power magnification fields (200X) in cortical-medullary  
148 junction, and MECA-32 in glomeruli was quantified by accounting positive glomerulus in cortex in  
149 five high-power magnification fields (100X). Quantification of  $\alpha$ -SMA staining in PTC were assessed  
150 by accounting positive PTC in ten high-power magnification fields (200X);  $\alpha$ -SMA staining in  
151 glomeruli was performed in five high-power magnification fields (100X). All assessments were done  
152 by two independent investigators blinded to experimental conditions.  $\alpha$ -SMA staining in renal  
153 microvessels was assessed using Visiomorph TM VIS Histoinformatics Software (Olympus) in the  
154 whole kidney.

155

### 156 **Sirius Red Staining**

157 Sirius Red staining was performed using Picro-Sirius Red Staining Kit (ab150681, Abcam,  
158 Cambridge, MA, USA) according to the manufacturer's instructions. All slides were scanned using  
159 an Olympus VS110 slide scanner microscope. Five randomly chosen high-power fields at the  
160 cortical-medullary junction (magnification 200X) were taken. Sirius red positive area within PTC and  
161 glomeruli were evaluated with ImageJ (National Institutes of Health) by two independent  
162 investigators blinded to experimental conditions.

163

### 164 **Silver staining**

165 Silver staining was done according to Jones' Methenamine Silver Stain (JMS) - Staining protocol  
166 ([29](#)). Stained slides were scanned using an Olympus VS110 slide scanner microscope. Five  
167 randomly chosen high-power fields in the renal cortical section (magnification 200X) were taken, and  
168 glomerulosclerosis scores were evaluated by two independent investigators blinded to experimental  
169 conditions. Based on involved glomerular percentage, glomerulosclerosis score was classified as 0-  
170 3 (0: no glomerulopathy-double contours affecting <10% peripheral capillary loop in the most severe  
171 attacked glomerulus. 1: double contours affecting up to 25% peripheral capillary loop in most  
172 affected non-sclerotic glomeruli. 2: double contours affecting up to 50% peripheral capillary loop in  
173 most affected non-sclerotic glomeruli. 3: double contours affecting >50% peripheral capillary loop in  
174 most affected non-sclerotic glomeruli) ([30](#)).

175

### 176 **Electron Microscopy**

177 Fresh murine renal tissue was fixed with 3% glutaraldehyde, post-fixed with 1% osmium tetroxide  
178 and embedded in Epon according to routine techniques. Ultrathin renal slices were obtained using  
179 an ultra-microtome (Leica Biosystems RM2245, Buffalo Grove, IL, USA) and mounted on naked  
180 nickel grids. Slices were stained with aqueous uranyl acetate and lead citrate as previously reported  
181 ([31](#)). Examination was performed using a Zeiss Axio Imager.A1 transmission electron microscope  
182 and electron micrographs were captured using a AxioCam, Zeiss digital camera. Images of renal

183 peritubular capillaries were taken randomly in the cortex and cortico-medullary junction by two  
184 blinded investigators.

185

### 186 **Ex-vivo renal microvasculacular microCT imaging**

187 5 mL silicone rubber radiopaque contrast agent Microfil (Flow Tech Inc. Carver, MA, USA) was  
188 pump-perfused (0.5ml/min, catheter length: 12cm) via a left ventricle 23G catheter to allow 3D  
189 visualization of the renal microvasculature. The kidney was collected following polymerization for 4-6  
190 hours at 4 °C and fixed in 1.5 mL tube for subsequent scan procedure ([32](#), [33](#)).

191 Ex-vivo micro-Computed Tomography (microCT) manipulation was performed using a high-  
192 resolution SkyScan 1176 scanner (SkyScan, Kontich, Belgium). The fixed kidney was positioned and  
193 scanned 360° around the vertical axis with a rotating speed of 0.3°, at a resolution of 9 µm. Vascular  
194 volume was assessed following volume rendering and 3D reconstruction analysis ([22](#)). Terminal  
195 capillaries were counted using Imaris 9.2 software (Oxford Instruments plc).

196

### 197 **Assessment of vascular permeability**

198 Evans Blue (E2129, Sigma Aldrich, Burlington, MA, USA) (5mg/kg) was dissolved in D-PBS 1X (1  
199 g/L glucose, 36 mg/L sodium pyruvate with calcium and magnesium) and injected intravenously via  
200 the tail vein. After 30 min of circulation, mice were perfused with 20 mL of 0,9% NaCl via the left  
201 ventricle to remove all the blood in the circulation. The ischemic kidney was collected, dried,  
202 weighed, and put in 100% formamide (4ml/g) at 56°C for 24h. Extracted Evans Blue was measured  
203 by spectrophotometry at 620 nm and expressed as mg/g bodyweight ([34](#), [35](#)).

204

### 205 **Intra-vital mice kidney imaging**

206 Intra-vital images were acquired using an upright Olympus FV1000 laser scanning confocal  
207 microscope (Olympus, Japan). At 21 days post-ischemia-reperfusion, mice were anesthetized with 2%  
208 isoflurane and 1% oxygen over all the surgery procedure and imaging session. Then mice were



209 placed on a 37°C heated blanket with the right jugular vein catheterized for the administration of  
210 reagents. The kidney was exposed by dorsal incision and positioned on a special stage (36). After  
211 preparation procedure, mice were maintained under a 32°C environment and were monitored using  
212 Mouse Ox apparatus (Flow Tech Inc). All images were acquired using a XLUM Plan FL N 20x/1.00  
213 Water objective. Ultrasound gel was used to establish the immersion between the objective and the  
214 coverslip (#1.5, 0.17 mm) as it has the same refractive index as water. 2000 kDa Alexa Fluor 488  
215 (AF488)-conjugated dextran (FD 2000S, Sigma Aldrich, Burlington, MA, USA) (0.25 mg/kg) and  
216 Evans Blue (1 mg/kg) were injected via a jugular catheter. Live imaging was taken at pre-injection  
217 and 15 minutes post-injection. For excitation, 405 nm, 488 nm and 635 nm lasers were used  
218 simultaneously for detection of autofluorescence (AF), Dextran AF488 and Evans Blue, respectively.  
219 For detection, photomultiplier tubes (PMT) detectors were configured as follows: for AF detection, a  
220 SDM490 dichroic mirror was positioned in front of the first PMT associated with a 430-470 nm  
221 emission filter; for Dextran AF488 detection, a SDM560 dichroic mirror was positioned in front of the  
222 second PMT, associated with a 505-605 nm emission filter; and for Evans Blue detection, a 655-755  
223 nm emission filter was positioned in front of the third detector. All channels were acquired  
224 simultaneously. Images were acquired in a 640x640 pixel format at zoom 3 (pixel resolution of 331  
225 nm) at 4  $\mu$ s/pixel speed at different time points after Evans Blue injection: prior to injection, 30 sec, 3  
226 min, 5 min, 10 min and 15 min post-injection. For live videos, the frame interval between each image  
227 was 2.4 seconds. During live acquisition, the sample was scanned in x and y at zoom 1X until a  
228 region of interest was observed during or after Evans Blue injection. The zoom was then adapted to  
229 Zoom 3X to focus on this specific region of the kidney. For some interesting time-points/localizations,  
230 z-stacks were acquired as followed: zoom 3X, step size 2  $\mu$ m, Z volume between 22  $\mu$ m up to 44  $\mu$ m  
231 depth. Images were acquired using the Olympus Fluoview software (v4.2.3.6, Olympus, Japan).  
232 Final images are 12 bits. Image analysis was performed using FIJI software (NIH, open source).  
233

234 Quantification of microvascular permeability was assessed by measuring the number of sites of  
235 Evans Blue accumulation per field of view. Capillary perfusion was evaluated by quantification of  
236 perfused versus non-perfused capillaries in each field. A capillary branch was defined as one  
237 segment between two nearby endpoints. Perfused capillaries with circulation were defined as  
238 yellow/green fluorescence in the lumen, and visible red blood cell circulation; non-perfused  
239 capillaries were defined as weak red fluorescence and the absence of cell circulation ([34](#)). Perfused  
240 capillaries without circulation were defined as yellow/green fluorescence in the lumen but without  
241 cellular circulation.

242

### 243 **Statistics**

244 All data were expressed as means  $\pm$  SEM. Biological and histological data were compared using  
245 unpaired *t*-test. Statistical analyses were performed using Prism 8 (Prism-GraphPad software, Inc).  
246 P values of 0.05 or less were considered significant.

247

### 248 **Study approval**

249 All animal experimental protocols (document number for animal use approval: 4114057MJHs and  
250 IP18047MJHs) were reviewed and approved by the Centre hospitalier de l'Université de Montréal -  
251 Comité Institutionnel de Protection des Animaux.

252

### 253 **Results**

#### 254 **Caspase-3 deficiency preserves long-term renal function after severe AKI.**

255 We showed previously that caspase-3 deficiency prevents microvascular rarefaction and long-term  
256 renal fibrosis after mild renal IRI despite early accentuation of tubular injury ([26](#)). We now compare  
257 the impact of caspase-3 deficiency in severe vs mild forms of IRI-induced AKI. Severe AKI was  
258 induced by clamping the renal artery for 60 minutes and mild AKI with renal artery clamping for 30  
259 minutes. Both interventions were followed by contralateral nephrectomy. Serum creatinine levels  
260 were significantly higher in severe AKI compared to mild AKI, both in wild-type and caspase-3<sup>-/-</sup> mice

261 at all time points (Fig. 1A). In caspase-3<sup>-/-</sup> mice, creatinine levels were significantly higher at day 1  
262 and 2 post-IRI in mild AKI compared with wild-type controls (Fig. 1B). In the severe AKI groups,  
263 there was no difference in serum creatinine levels between caspase-3<sup>-/-</sup> mice and wild-type controls  
264 during the first-week post-IRI. At day 21 post-IRI, serum creatinine failed to go back to baseline in  
265 both wild-type and caspase-3<sup>-/-</sup> mice with severe AKI (Fig. 1A). Serum creatinine levels were  
266 statistically lower in caspase-3<sup>-/-</sup> mice with severe AKI compared with wild-type controls with severe  
267 AKI but there was no significant difference in mild AKI. Caspase-3<sup>-/-</sup> mice showed higher tubular  
268 injury scores than wild-type controls in both mild and severe AKI at day 1 post-IRI. These results are  
269 in line with our previous findings showing redirection towards tubular necroptosis in caspase-3<sup>-/-</sup> mice  
270 in the early phase of AKI (26). On day 21 post-IRI, tubular injury scores were significantly better in  
271 caspase-3<sup>-/-</sup> mice compared to wild-type controls in both severe and mild AKI (Fig. 1B). Collectively,  
272 these results demonstrate that the severity of IRI predicts long-term renal dysfunction while early  
273 tubular injury does not predict long-term tubular integrity and level of renal dysfunction (Fig. 1B, Fig.  
274 S1A).

275

### 276 **Caspase-3 deficiency improves long-term renal microvascular integrity and rarefaction after** 277 **mild and severe forms of IRI-induced AKI.**

278 Microvascular rarefaction is increasingly recognized as an important determinant of progressive  
279 renal failure after AKI (24, 37, 38). Therefore, we turned to evaluating the impact of caspase-3 on  
280 microvascular integrity in mild and severe forms of AKI (37). Rouleaux formation, a read-out of  
281 microvascular congestion, increased in the early phase of AKI in wild-type mice submitted to 30 min  
282 of artery clamping and increased further on the long term, suggesting sustained and progressive  
283 abnormalities in microvascular circulation (Fig. 1C). Caspase-3<sup>-/-</sup> mice showed significantly lower  
284 rouleaux levels both in the early (day 1) and chronic (day 21) phases of mild AKI (Fig. 1C, Fig. S1B).  
285 Intriguingly, severe AKI was associated with lower levels of rouleaux formation in wild-type and  
286 caspase-3<sup>-/-</sup> mice compared to mild AKI. Rouleaux formation at day 21 was significantly lower in

287 caspase-3<sup>-/-</sup> mice with severe AKI compared with wild-type mice. These results suggest better  
288 preservation of microvascular circulation in caspase-3<sup>-/-</sup> mice, both in mild and severe forms of AKI.  
289 The lower levels of rouleaux formation with severe AKI were surprising and raised the possibility of  
290 enhanced microvascular rarefaction with severe AKI, preventing microvascular circulation and hence  
291 rouleaux formation. To test this possibility, we used immunostaining of murine endothelial cell  
292 antigen-32 (MECA-32), a marker of microvascular endothelial cells (34). On day 21 post-IRI, MECA-  
293 32 staining in cortico-medullary PTC was significantly reduced in wild-type mice exposed to mild AKI  
294 compared to sham-treated animals. MECA-32 was further reduced in wild-type mice exposed to  
295 severe AKI compared to sham. In both forms of AKI, caspase-3<sup>-/-</sup> mice showed significantly higher  
296 PTC MECA-32 staining than wild-type counterparts. (Fig. 2A, Fig. S2). Electron microscopy also  
297 revealed the preservation of microvascular integrity in caspase-3<sup>-/-</sup> mice. Features of endothelial  
298 apoptosis, such as nuclear condensation, apoptotic bodies, apoptotic exosome-like vesicles, were  
299 found within PTC in wild-type but not in the caspase-3<sup>-/-</sup> mice (Fig. 3A-F). Rouleaux formation was  
300 also observed in PTC of wild-type mice, consistent with results on HE-stained tissue (Fig.1C). Wild-  
301 type mice also showed reduced endothelial fenestration and basement membrane irregularities at 21  
302 d post-IRI (Fig. 3A-C). These features were limited in caspase-3<sup>-/-</sup> mice, where microvascular  
303 integrity was better preserved. (Fig. 3D-F). Caspase-3 immunohistochemistry staining revealed the  
304 presence of several positive endothelial-like cells within PTC in wild-type mice at 21 days post  
305 severe IRI (Fig. S3) unlike caspase-3<sup>-/-</sup> mice. Collectively, these results showed enhanced  
306 microvascular rarefaction with more severe forms of AKI and better PTC preservation in caspase-3  
307 deficient mice. We also evaluated whether microvascular compartments other than PTC show  
308 differences in MECA-32 staining post-AKI. Glomerular MECA-32 staining was not modulated by AKI  
309 in wild-type or caspase-3<sup>-/-</sup> mice (Fig. 2B). In line with this result, glomerulosclerosis was not  
310 modulated post-AKI (Fig. S4). To further confirm these results, we assessed microvascular  
311 rarefaction with contrast-enhanced microCT. Total blood vessel volume decreased at day 21 post-  
312 IRI in mild and severe AKI when compared to baseline. There was however no significant difference  
313 between wild type and caspase-3<sup>-/-</sup> mice (Fig. 4). However, significant differences were noted when

314 considering terminal capillary volume. In wild-type mice, the number of terminal capillaries was lower  
315 than baseline in mild AKI and there was a further significant reduction in severe AKI. Caspase-3<sup>-/-</sup>  
316 mice showed significantly higher terminal capillary numbers than wild-type counterparts after mild  
317 and severe AKI (Fig. 4C). Collectively, these results demonstrate the importance of caspase-3 in  
318 controlling microvascular rarefaction in both mild and severe forms of AKI.

319

### 320 **Caspase-3 deficiency prevents endothelial permeability disorder after mild and severe AKI.**

321 Abnormal microvascular permeability is another feature of AKI to CKD transition and is thought to  
322 contribute to the development of a hypoxic microenvironment that fuels fibrogenesis, tubular injury  
323 and renal failure (37). We evaluated endothelial permeability post-IRI using intra-vital confocal  
324 microscopy. Mice were injected with fluorescein isothiocyanate–labeled high molecular weight (2000  
325 kDa) dextran to delineate the vasculature and with red fluorescent Evans Blue to detect  
326 extravasation. Evans Blue binds to albumin, which make it capable of labeling the endothelial sites  
327 of albumin leakage. At day 21 post-IRI, wild-type mice with mild AKI showed abnormal PTC  
328 permeability with significantly increased global kidney Evans Blue extravasation compared with  
329 sham-treated mice (Fig. 5D). Caspase-3<sup>-/-</sup> mice with mild AKI showed reduced Evans Blue  
330 extravasation when compared to wild-type controls. There was however no difference between wild-  
331 type and caspase-3<sup>-/-</sup> mice with severe AKI. We went on to characterize microscopic differences.  
332 Wild-type mice exposed to mild AKI showed areas of extravasation, the number of which was further  
333 enhanced in wild-type mice exposed to severe AKI. These extravasation areas were characterized  
334 by the presence of extravascular Evans Blue but not 2000 kDa dextran. We observed the  
335 appearance of Evans Blue within the peritubular or tubular lumen shortly after I.V. administration  
336 suggesting respectively PTC and glomerular filtration barrier dysfunction after IRI (video 5-8). By  
337 performing intra-vital imaging, we could also assess microvascular perfusion in real time. In both  
338 mild and severe AKI, caspase-3<sup>-/-</sup> mice showed significantly reduced length of non-perfused PTC  
339 when compared to wild-type mice (Fig. 5A, B, Video 1, 2, Fig. S5). The ratio of perfused capillaries  
340 decreased in wild-type mice exposed to mild AKI when compared to baseline and the decrease was

341 further enhanced in wild-type mice exposed to severe AKI (Fig. 5C). Caspase-3<sup>-/-</sup> kidneys showed a  
342 higher number of perfused capillaries in mild and severe AKI as compared to wild-type kidneys (Fig.  
343 5C, Video 3, Video 4, Fig. S6, Video 9). Prevention of PTC rarefaction leading to preservation of  
344 tubule perfusion was also reflected by lower expression of tubular HIF-1a in caspase-3<sup>-/-</sup> mice at 21  
345 days post-IRI both in the cortex and cortico-medullary junction (Fig. S7). Collectively, these results  
346 demonstrate that AKI of increasing severity leads to enhanced permeability disturbances and that  
347 caspase-3 controls microvascular integrity and permeability after mild and severe AKI.

348

### 349 **Caspase-3 deficiency prevents renal fibrogenesis after AKI.**

350 Progressive renal failure is classically accompanied by fibrosis characterized by increased collagen  
351 deposition and interstitial myofibroblast differentiation. Renal microvascular disturbances are  
352 frequently associated with renal fibrogenesis although recent data suggest that this association may  
353 not always hold true (24). Staining with Sirius red, a marker of collagen I and III, revealed a  
354 significant increase in peritubular collagen deposition at day 21 post-IRI in wild-type mice exposed to  
355 mild and severe AKI. Caspase-3 deficient mice showed reduced collagen deposition as compared  
356 with wild-type controls in both mild and severe forms of AKI (Fig. 6A). Increased collagen deposition  
357 with AKI was not present in all microvascular compartments as Sirius red staining in glomeruli was  
358 not modulated by AKI in wild-type or caspase-3<sup>-/-</sup> mice at day 21 post-IRI (Fig. 6B). Electron  
359 microscopy confirmed the accumulation of collagen within the peritubular basement membrane in  
360 wild-type mice (Fig. 6C).

361 Myofibroblast differentiation, as evaluated with alpha-smooth muscle actin ( $\alpha$ -SMA) staining, was  
362 assessed in PTC and glomeruli. On day 21 post-IRI, wild-type mice showed increased peritubular  $\alpha$ -  
363 SMA staining in both forms of AKI. In both mild and severe forms of AKI, caspase-3<sup>-/-</sup> mice  
364 demonstrated less myofibroblast differentiation within renal PTC (Fig. 7A, B). However, there was no  
365 difference in  $\alpha$ -SMA staining within glomeruli or macrovessels between wild-type or caspase-3  
366 deficient mice (Fig. 7C, D). Collectively, these results highlight the association between PTC

367 abnormalities and fibrogenesis and confirm the protective role of caspase-3 deficiency in preventing  
368 peritubular fibrosis.

369

## 370 **Discussion**

371 Microvascular rarefaction is increasingly appreciated as an important predictor of AKI to CKD  
372 transition following ischemia-reperfusion injury. Here we show that caspase-3 is a pivotal regulator of  
373 peritubular microvascular integrity and long-term dysfunction after IRI. The severity of acute IRI  
374 correlates in the long term with the severity of microvascular rarefaction, fibrosis, and loss of renal  
375 function. Severe AKI also leads to greater long-term perturbation of renal microvascular permeability  
376 (Fig. 8). We identify caspase-3 as a pivotal factor controlling microvascular homeostasis and renal  
377 function post-IRI. These results extend our previous observations pointing to an important role for  
378 caspase-3 in the regulation of microvascular rarefaction following mild IRI. In this study, we show  
379 that in mild and severe forms of AKI, caspase-3 control not only the number of surviving peritubular  
380 capillaries but also impacts their permeability and overall tubule-interstitial oxygenation. The  
381 beneficial impact of caspase-3 deficiency on long-term renal outcomes is present despite the early  
382 deterioration of epithelial injury, both in mild and severe forms of AKI, confirming the predominant  
383 role of microvascular injury over early epithelial damage in regulating AKI to CKD transition.

384 A number of different murine IRI models ([39-42](#)) are available to investigate the pathophysiology of  
385 AKI-to-CKD transition. However, severe forms of AKI are less commonly investigated given the  
386 difficulty of ensuring animal survival in the long term ([43](#), [44](#)). Head-to-head comparisons of  
387 microvascular abnormalities after mild and severe IRI are therefore still lacking. Yet severe AKI is  
388 an important cause of progressive renal dysfunction in patients ([45](#)) and efforts are needed to better  
389 understand the mechanisms contributing to progressive renal failure in this context. In this study, we  
390 used unilateral renal artery clamping for 30 and 60 minutes along with contralateral nephrectomy, as  
391 means of comparing mild and severe forms of IRI on AKI-to-CKD transition. As expected, severe  
392 AKI led to higher serum creatinine levels at all time points when compared to mild AKI. Intriguingly,

393 indices of microvascular congestion 2 days and 3 weeks after IRI were significantly less important in  
394 severe AKI compared to mild AKI. This finding led us to consider the possibility that severe IRI  
395 aggravates microvascular drop-out. In that case, congestion indices would be reduced not because  
396 of better microvascular integrity but rather by the disappearance of the microvascular network. Our  
397 results largely support this assumption. Immunohistochemistry for MECA-32, electron microscopy  
398 and *in vivo* imaging with 3D integral renal vasculature visualization confirmed enhanced and  
399 accelerated microvascular rarefaction with increased severity of IRI. Caspase-3 deficiency led to  
400 better preservation of the renal peritubular microvasculature both in mild and severe forms of AKI.  
401 3D reconstructed kidney from microCT imaging showed enhanced reduction of terminal capillary  
402 volume with increasing severity of IRI and preservation of capillary volume in caspase-3 deficient  
403 animals. Microvascular analysis along with endothelial staining confirmed PTC rarefaction but  
404 showed no difference in glomerular histology in both forms of AKI. These findings are in line with  
405 observations showing little ultrastructural alterations of glomerular endothelial membranes following  
406 renal ischemia-reperfusion injury ([46](#), [47](#)).

407 Our results also point to caspase-3 as a pivotal regulator of PTC injury and dysfunction. IRI triggers  
408 breaks of intercellular adhesions leading to increased PTC permeability exemplified by leakiness of  
409 the contrast agent ([48](#)). Enhanced permeability likely represents a compensation mechanism aimed  
410 at preserving tissue perfusion after ischemia. However, in the long-term, leakiness leads to  
411 interstitial edema, capillary compression, and further perturbations in perfusion and oxygenation ([49](#)).

412 Using intra-vital kidney imaging, we found abnormal PTC leakiness with mild IRI and further  
413 enhanced permeability abnormalities with severe IRI. Enhanced capillary rarefaction with severe IRI  
414 was associated with more severe permeability disturbances and higher tubular expression of HIF-1 $\alpha$ .  
415 Conversely, caspase-3 deficiency protected against permeability disturbances and microvascular  
416 drop-out and was associated with lower HIF-1 $\alpha$  tubular levels. These results are in line with previous  
417 findings suggesting a major role for microvascular injury in fueling tubular ischemia that can, in turn,  
418 contribute to CKD transition ([50](#)). Microvascular permeability disturbances similar to the ones we



419 described after severe IRI injury have been reported in association with a number of animal models  
420 of renal dysfunction such as ureteral obstruction and Col4a3-deficient mice, and in patient biopsy  
421 samples with progressive renal failure due to glomerulonephritis and interstitial nephritis (34). These  
422 similarities raise the possibility that microvascular rarefaction and permeability disturbances  
423 represent a common pathway of transition toward progressive loss of renal function, irrespective of  
424 the initial cause of renal dysfunction.

425 Renal fibrosis is a classical hallmark of progressive renal failure. The present work highlights a close  
426 association between the severity of microvascular disturbances, level of peritubular fibrosis, and loss  
427 of renal function. There was however no correlation between indices of early tubular injury and long-  
428 term renal fibrosis or renal function. In caspase-3 deficient mice, early renal dysfunction and tubular  
429 injury scores were worse than wild-type controls in both forms of IRI. Yet caspase-3 deficient mice  
430 showed lower renal fibrosis and reduced dysfunction in the long term. Collectively, our results point  
431 to the importance of turning our attention to markers of microvascular injury as potential predictors of  
432 AKI to CKD transition. Currently, AKI severity is evaluated with clinical criteria, such as an increase  
433 in serum creatinine, decreased urine output, and the need for renal replacement therapy. Most  
434 biomarkers of AKI, such as cystatin C, kidney-injury-molecule-1 (KIM-1), and neutrophil gelatinase-  
435 associated lipocalin (NGAL) monitor levels of tubular injury (51, 52). However, the present results  
436 and an increasing body of literature suggest that early tubular injury is unlikely to predict transition to  
437 CKD if not associated with concomitant microvascular injury and PTC drop-out (53, 54). There is an  
438 urgent need for biomarkers that could allow a reliable and non-invasive assessment of the degree of  
439 PTC damage following IRI. Several new candidates are emerging and should be the scope of future  
440 studies. Our group showed that endothelial cells release apoptotic exosome-like membrane vesicles  
441 which can be tracked in circulation following ischemia-reperfusion episodes, including renal IRI (55).  
442 Several endothelial associated proteins and molecules have been considered as potential biomarker  
443 candidates at an early stage, such as E-selectin, P-selectin, vascular endothelial growth factor  
444 (VEGF), glycocalyx, endothelin-1, angiopoietins, intercellular adhesion molecule (ICAM), vascular

445 cell adhesion molecule (VCAM) ([56-62](#)). It will be crucial to assess the capacity of these biomarkers  
446 and others to predict AKI to CKD transition and long-term renal outcomes after IRI. As acute  
447 microvascular dysfunction following IRI has been documented in lungs, liver and intestine ([63-66](#)),  
448 better means of assessing microvascular damage could prove useful in delineating the relationship  
449 between microvascular drop-out and fibrosis in a number of conditions.

450 Our results also point to caspase-3 as a potential target of intervention for the prevention of CKD  
451 transition following AKI. Caspase-3 inhibitors and siRNA have been tested on early renal outcomes  
452 in a number of IRI animal models with somewhat conflicting results ([67-70](#)). Caspase-3 siRNA  
453 intervention also displayed a protective role on renal function in a porcine kidney autotransplant  
454 model ([70](#)). Although caspase inhibition has yet to be tested in human renal IRI, a pan-caspase  
455 inhibitor has been evaluated in clinical trials in the context of liver transplantation (NCT00080236),  
456 IDNN-6556 (pan-caspase inhibitor) administration in cold perfusate protected liver damage against  
457 IRI initiated apoptosis ([71](#)). But, to our knowledge, only early time points were assessed. Further  
458 clinical studies addressing the use of caspase inhibition in the prevention of progressive renal  
459 dysfunction after IRI are still lacking. Our current results point to the need to address this question in  
460 future clinical studies that will look into acute and long-term consequences of renal IRI in patients.

461 In conclusion, the severity of PTC disturbances after IRI is a major predictor of AKI to CKD transition.  
462 Caspase-3 is an important mediator in AKI, due to its crucial regulatory effect on apoptosis and its  
463 downstream consequence on microvascular function and rarefaction, fibrogenesis, and renal  
464 function post-IRI. These results open new directions for defining predictors of AKI to CKD transition  
465 and identify caspase-3 as a novel target of intervention for preserving long-term renal function.

466

#### 467 **Author contributions**

468 S.L. and M.J.H. conceived and designed the research strategy. S.L. and B.Y. performed experiments.  
469 S.L., B.Y., M.J.H., M.J.H., and N.P. analyzed the slides, images and videos. S.L., B.Y., F.M., J.T.,  
470 M.B., M.D. analyzed data. S.L., B.Y., F.M., J.T., M.D., M.J.H., H.C., and M.J.H. interpreted the results.

471 S.L. and F.M. prepared figures. S.L., F.M., and M.J.H. drafted the manuscript. S.L., F.M., H.C., and  
472 M.J.H. edited and revised the manuscript. S.L., B.Y., F.M., J.T., M.B., M.D., M.J.H., H.C., N.P., and  
473 M.J.H. approved the final version of the manuscript.

474

## 475 **Acknowledgment**

476 The authors acknowledge support from the Canadian Institutes of Health Research (MOP-123436  
477 and PJT-148884) and the Canadian Donation Transplantation Research Program (CDTRP). Marie-  
478 Josée Hébert holds the Shire Chair in Nephrology, Transplantation and Renal Regeneration of  
479 Université de Montréal. We also thank the J.-L. Lévesque Foundation for renewed support.  
480 Shanshan Lan was supported by the Canadian Society of Transplantation (CST) Research Training  
481 Award and is a CDTRP trainee. We thank Dr. Junzheng Peng of the Cardiovascular phenotype core  
482 facility of the Centre Hospitalier de l'Université de Montréal Research Centre (CRCHUM) for  
483 assisting in microCT imaging and Dr. Aurélie Cleret-Buhot of the Cell Imaging core facility of the  
484 CRCHUM for performing the confocal microscopy acquisitions. We thank the CRCHUM molecular  
485 pathology platform and animal facility for their service. Many thanks to Dr. Shijie Qi for thoughtful  
486 advice and to Hyunyun Kim for his assistance with murine renal pathology evaluation. Also great  
487 thanks to Dr. Kejia Zhang for his drawing contribution in Figure 8 and graphic abstract.

488 The authors have no conflict of interest to declare.

## 489 **References**

- 490 1. Chawla LS, Eggers PW, Star RA, and Kimmel PL. Acute kidney injury and chronic  
491 kidney disease as interconnected syndromes. *N Engl J Med.* 2014;371(1):58-66.
- 492 2. Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, et al.  
493 World incidence of AKI: a meta-analysis. *Clin J Am Soc Nephrol.* 2013;8(9):1482-93.  
494 doi: 10.2215/CJN.00710113. Epub 2013 Jun 6.
- 495 3. Bedford M, Farmer C, Levin A, Ali T, and Stevens P. Acute kidney injury and CKD:  
496 chicken or egg? *Am J Kidney Dis.* 2012;59(4):485-91. doi: 10.1053/j.ajkd.2011.09.010.
- 497 4. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al. Acute  
498 kidney injury increases risk of ESRD among elderly. *J Am Soc Nephrol.* 2009;20(1):223-  
499 8. doi: 10.1681/ASN.2007080837. Epub 2008 Nov 19.
- 500 5. Molitoris BA. Therapeutic translation in acute kidney injury: the epithelial/endothelial  
501 axis. *J Clin Invest.* 2014;124(6):2355-63. doi: 10.1172/JCI72269. Epub 2014 Jun 2.

- 502 6. Cavaille-Coll M, Bala S, Velidedeoglu E, Hernandez A, Archdeacon P, Gonzalez G, et al.  
503 Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation. *Am*  
504 *J Transplant*. 2013;13(5):1134-48.
- 505 7. Lechevallier E, Dussol B, Luccioni A, Thirion X, Vacher-Copomat H, Jaber K, et al.  
506 Posttransplantation acute tubular necrosis: risk factors and implications for graft survival.  
507 *Am J Kidney Dis*. 1998;32(6):984-91.
- 508 8. Irish WD, McCollum DA, Tesi RJ, Owen AB, Brennan DC, Bailly JE, et al. Nomogram  
509 for predicting the likelihood of delayed graft function in adult cadaveric renal transplant  
510 recipients. *J Am Soc Nephrol*. 2003;14(11):2967-74.
- 511 9. Amdur RL, Chawla LS, Amodeo S, Kimmel PL, and Palant CE. Outcomes following  
512 diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. *Kidney*  
513 *Int*. 2009;76(10):1089-97. doi: 10.38/ki.2009.332. Epub Sep 9.
- 514 10. Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordonez JD, et al. Dialysis-  
515 requiring acute renal failure increases the risk of progressive chronic kidney disease.  
516 *Kidney Int*. 2009;76(8):893-9. doi: 10.1038/ki.2009.289. Epub Jul 29.
- 517 11. Yarlagadda SG, Coca SG, Formica RN, Poggio ED, and Parikh CR. Association between  
518 delayed graft function and allograft and patient survival: a systematic review and meta-  
519 analysis. *Nephrol Dial Transpl*. 2009;24(3):1039-47.
- 520 12. Legendre C, Canaud G, and Martinez F. Factors influencing long-term outcome after  
521 kidney transplantation. *Transpl Int*. 2014;27(1):19-27.
- 522 13. Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, and Dong Z. Regulated  
523 cell death in AKI. *J Am Soc Nephrol*. 2014;25(12):2689-701.
- 524 14. Sharfuddin AA, and Molitoris BA. Pathophysiology of ischemic acute kidney injury. *Nat*  
525 *Rev Nephrol*. 2011;7(4):189-200. doi: 10.1038/nrneph.2011.16. Epub Mar 1.
- 526 15. Basile DP. The endothelial cell in ischemic acute kidney injury: implications for acute  
527 and chronic function. *Kidney Int*. 2007;72(2):151-6. Epub 2007 May 2.
- 528 16. Basile DP, Friedrich JL, Spahic J, Knipe N, Mang H, Leonard EC, et al. Impaired  
529 endothelial proliferation and mesenchymal transition contribute to vascular rarefaction  
530 following acute kidney injury. *Am J Physiol Renal Physiol*. 2011;300(3):F721-33. doi:  
531 10.1152/ajprenal.00546.2010. Epub 2010 Dec 1.
- 532 17. Horbelt M, Lee SY, Mang HE, Knipe NL, Sado Y, Kribben A, et al. Acute and chronic  
533 microvascular alterations in a mouse model of ischemic acute kidney injury. *Am J*  
534 *Physiol Renal Physiol*. 2007;293(3):F688-95. Epub 2007 Jul 11.
- 535 18. Basile DP, Donohoe DL, Roethe K, and Mattson DL. Chronic renal hypoxia after acute  
536 ischemic injury: effects of L-arginine on hypoxia and secondary damage. *Am J Physiol*  
537 *Renal Physiol*. 2003;284(2):F338-48. Epub 2002 Oct 1.
- 538 19. Basile DP, Donohoe D, Roethe K, and Osborn JL. Renal ischemic injury results in  
539 permanent damage to peritubular capillaries and influences long-term function. *Am J*  
540 *Physiol Renal Physiol*. 2001;281(5):F887-99.
- 541 20. Basile DP, and Yoder MC. Renal endothelial dysfunction in acute kidney ischemia  
542 reperfusion injury. *Cardiovasc Hematol Disord Drug Targets*. 2014;14(1):3-14.
- 543 21. Steegh FM, Gelens MA, Nieman FH, van Hooff JP, Cleutjens JP, van Suylen RJ, et al.  
544 Early loss of peritubular capillaries after kidney transplantation. *J Am Soc Nephrol*.  
545 2011;22(6):1024-9. doi: 10.681/ASN.2010050531. Epub 2011 May 12.
- 546 22. Ehling J, Babickova J, Gremse F, Klinkhammer BM, Baetke S, Knuechel R, et al.  
547 Quantitative Micro-Computed Tomography Imaging of Vascular Dysfunction in

- 548 Progressive Kidney Diseases. *J Am Soc Nephrol*. 2016;27(2):520-32. doi:  
549 10.1681/ASN.2015020204. Epub 2015 Jul 20.
- 550 23. Babickova J, Klinkhammer BM, Buhl EM, Djudjaj S, Hoss M, Heymann F, et al.  
551 Regardless of etiology, progressive renal disease causes ultrastructural and functional  
552 alterations of peritubular capillaries. *Kidney Int*. 2017;91(1):70-85. doi:  
553 10.1016/j.kint.2016.07.038. Epub Sep 24.
- 554 24. Menshikh A, Scarfe L, Delgado R, Finney C, Zhu Y, Yang H, et al. Capillary rarefaction  
555 is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and  
556 ischemia-reperfusion-induced AKI than renal fibrosis. *Am J Physiol Renal Physiol*.  
557 2019;317(5):F1383-F97.
- 558 25. Zhang X, Zheng X, Sun H, Feng B, Chen G, Vladau C, et al. Prevention of renal  
559 ischemic injury by silencing the expression of renal caspase 3 and caspase 8.  
560 *Transplantation*. 2006;82(12):1728-32.
- 561 26. Yang B, Lan S, Dieude M, Sabo-Vatasescu JP, Karakeussian-Rimbaud A, Turgeon J, et  
562 al. Caspase-3 Is a Pivotal Regulator of Microvascular Rarefaction and Renal Fibrosis  
563 after Ischemia-Reperfusion Injury. *J Am Soc Nephrol*. 2018;29(7):1900-16.
- 564 27. Yang B, Dieude M, Hamelin K, Henault-Rondeau M, Patey N, Turgeon J, et al. Anti-  
565 LG3 Antibodies Aggravate Renal Ischemia-Reperfusion Injury and Long-Term Renal  
566 Allograft Dysfunction. *American journal of transplantation : official journal of the  
567 American Society of Transplantation and the American Society of Transplant Surgeons*.  
568 2016;16(12):3416-29.
- 569 28. Langenberg C, Gobe G, Hood S, May CN, and Bellomo R. Renal histopathology during  
570 experimental septic acute kidney injury and recovery. *Crit Care Med*. 2014;42(1):e58-67.
- 571 29. Chow BSM, and Allen TJ. Mouse Models for Studying Diabetic Nephropathy. *Curr  
572 Protoc Mouse Biol*. 2015;5(2):85-94.
- 573 30. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97  
574 working classification of renal allograft pathology. *Kidney Int*. 1999;55(2):713-23.
- 575 31. Sirois I, Groleau J, Pallet N, Brassard N, Hamelin K, Londono I, et al. Caspase activation  
576 regulates the extracellular export of autophagic vacuoles. *Autophagy*. 2012;8(6):927-37.
- 577 32. Ehling J, Babickova J, Gremse F, Klinkhammer BM, Baetke S, Knuechel R, et al.  
578 Quantitative Micro-Computed Tomography Imaging of Vascular Dysfunction in  
579 Progressive Kidney Diseases. *J Am Soc Nephrol*. 2016;27(2):520-32.
- 580 33. Ghanavati S, Yu LX, Lerch JP, and Sled JG. A perfusion procedure for imaging of the  
581 mouse cerebral vasculature by X-ray micro-CT. *J Neurosci Methods*. 2014;221:70-7.
- 582 34. Babickova J, Klinkhammer BM, Buhl EM, Djudjaj S, Hoss M, Heymann F, et al.  
583 Regardless of etiology, progressive renal disease causes ultrastructural and functional  
584 alterations of peritubular capillaries. *Kidney Int*. 2017;91(1):70-85.
- 585 35. Ferrero ME. In vivo vascular leakage assay. *Methods Mol Med*. 2004;98:191-8.
- 586 36. Westhorpe CL, Bayard JE, O'Sullivan KM, Hall P, Cheng Q, Kitching AR, et al. In Vivo  
587 Imaging of Inflamed Glomeruli Reveals Dynamics of Neutrophil Extracellular Trap  
588 Formation in Glomerular Capillaries. *Am J Pathol*. 2017;187(2):318-31.
- 589 37. Molitoris BA. Therapeutic translation in acute kidney injury: the epithelial/endothelial  
590 axis. *J Clin Invest*. 2014;124(6):2355-63.
- 591 38. Basile DP. The case for capillary rarefaction in the AKI to CKD progression: insights  
592 from multiple injury models. *Am J Physiol Renal Physiol*. 2019;317(5):F1253-F4.

- 593 39. Zager RA, Johnson ACM, Andress D, and Becker K. Progressive endothelin-1 gene  
594 activation initiates chronic/end-stage renal disease following experimental  
595 ischemic/reperfusion injury. *Kidney International*. 2013;84(4):703-12.
- 596 40. Basile DP, Donohoe D, Roethe K, and Osborn JL. Renal ischemic injury results in  
597 permanent damage to peritubular capillaries and influences long-term function. *Am J*  
598 *Physiol Renal Physiol*. 2001;281(5):F887-99.
- 599 41. Yang L, Besschetnova TY, Brooks CR, Shah JV, and Bonventre JV. Epithelial cell cycle  
600 arrest in G2/M mediates kidney fibrosis after injury. *Nat Med*. 2010;16(5):535-43, 1p  
601 following 143.
- 602 42. Grgic I, Campanholle G, Bijol V, Wang C, Sabbisetti VS, Ichimura T, et al. Targeted  
603 proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. *Kidney Int*.  
604 2012;82(2):172-83.
- 605 43. Fu Y, Tang C, Cai J, Chen G, Zhang D, and Dong Z. Rodent models of AKI-CKD  
606 transition. *Am J Physiol Renal Physiol*. 2018;315(4):F1098-F106.
- 607 44. Skrypnik NI, Harris RC, and de Caestecker MP. Ischemia-reperfusion Model of Acute  
608 Kidney Injury and Post Injury Fibrosis in Mice. *Jove-J Vis Exp*. 2013(78).
- 609 45. Forni LG, Darmon M, Ostermann M, Oudemans-van Straaten HM, Pettila V, Prowle JR,  
610 et al. Renal recovery after acute kidney injury. *Intensive Care Med*. 2017;43(6):855-66.
- 611 46. Rippe C, Rippe A, Larsson A, Asgeirsson D, and Rippe B. Nature of glomerular capillary  
612 permeability changes following acute renal ischemia-reperfusion injury in rats. *Am J*  
613 *Physiol Renal Physiol*. 2006;291(6):F1362-8.
- 614 47. Picken M, Long J, Williamson GA, and Polichnowski AJ. Progression of Chronic Kidney  
615 Disease After Acute Kidney Injury: Role of Self-Perpetuating Versus Hemodynamic-  
616 Induced Fibrosis. *Hypertension*. 2016;68(4):921-8.
- 617 48. Sutton TA, Mang HE, Campos SB, Sandoval RM, Yoder MC, and Molitoris BA. Injury  
618 of the renal microvascular endothelium alters barrier function after ischemia. *Am J*  
619 *Physiol Renal Physiol*. 2003;285(2):F191-8.
- 620 49. Olof P, Hellberg A, Kallskog O, and Wolgast M. Red cell trapping and postischemic  
621 renal blood flow. Differences between the cortex, outer and inner medulla. *Kidney Int*.  
622 1991;40(4):625-31.
- 623 50. Sutton TA. Alteration of microvascular permeability in acute kidney injury. *Microvasc*  
624 *Res*. 2009;77(1):4-7.
- 625 51. Ko GJ, Grigoryev DN, Linfert D, Jang HR, Watkins T, Cheadle C, et al. Transcriptional  
626 analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1  
627 as biomarkers of AKI-to-CKD transition. *Am J Physiol Renal Physiol*.  
628 2010;298(6):F1472-83.
- 629 52. Schaub JA, and Parikh CR. Biomarkers of acute kidney injury and associations with  
630 short- and long-term outcomes. *F1000Res*. 2016;5.
- 631 53. Chou YH, Huang TM, and Chu TS. Novel insights into acute kidney injury-chronic  
632 kidney disease continuum and the role of renin-angiotensin system. *Journal of the*  
633 *Formosan Medical Association*. 2017;116(9):652-9.
- 634 54. Devarajan P. The Use of Targeted Biomarkers for Chronic Kidney Disease. *Adv Chronic*  
635 *Kidney D*. 2010;17(6):469-79.
- 636 55. Sirois I, Raymond MA, Brassard N, Cailhier JF, Fedjaev M, Hamelin K, et al. Caspase-3-  
637 dependent export of TCTP: a novel pathway for antiapoptotic intercellular  
638 communication. *Cell death and differentiation*. 2011;18(3):549-62.

- 639 56. Futrakul N, and Futrakul P. Biomarker for early renal microvascular and diabetic kidney  
640 diseases. *Ren Fail.* 2017;39(1):505-11.
- 641 57. Cardinal H, Dieude M, and Hebert MJ. Endothelial Dysfunction in Kidney  
642 Transplantation. *Front Immunol.* 2018;9:1130.
- 643 58. Dieude M, Bell C, Turgeon J, Beillevaire D, Pomerleau L, Yang B, et al. The 20S  
644 proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody  
645 production and accelerates rejection. *Sci Transl Med.* 2015;7(318):318ra200.
- 646 59. Chade AR. Small Vessels, Big Role: Renal Microcirculation and Progression of Renal  
647 Injury. *Hypertension.* 2017;69(4):551-63.
- 648 60. Ohnishi Y, Yasudo H, Suzuki Y, Furuta T, Matsuguma C, Azuma Y, et al. Circulating  
649 endothelial glycocalyx components as a predictive marker of coronary artery lesions in  
650 Kawasaki disease. *Int J Cardiol.* 2019;292:236-40.
- 651 61. Powell TC, Powell SL, Allen BK, Griffin RL, Warnock DG, and Wang HE. Association  
652 of inflammatory and endothelial cell activation biomarkers with acute kidney injury after  
653 sepsis. *Springerplus.* 2014;3:207.
- 654 62. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, and Tedgui A.  
655 Endothelial microparticles in diseases. *Cell Tissue Res.* 2009;335(1):143-51.
- 656 63. Xu J, Buchwald JE, and Martins PN. Review of Current Machine Perfusion Therapeutics  
657 for Organ Preservation. *Transplantation.* 2020;104(9):1792-803.
- 658 64. Ferrari RS, and Andrade CF. Oxidative Stress and Lung Ischemia-Reperfusion Injury.  
659 *Oxidative Medicine and Cellular Longevity.* 2015;2015:1-14.
- 660 65. Feltes CM, Hassoun HT, Lie ML, Cheadle C, and Rabb H. Pulmonary endothelial cell  
661 activation during experimental acute kidney injury. *Shock.* 2011;36(2):170-6.
- 662 66. Gonzalez LM, Moeser AJ, and Blikslager AT. Animal models of ischemia-reperfusion-  
663 induced intestinal injury: progress and promise for translational research. *Am J Physiol*  
664 *Gastrointest Liver Physiol.* 2015;308(2):G63-75.
- 665 67. Homsí E, Janino P, and de Faria JB. Role of caspases on cell death, inflammation, and  
666 cell cycle in glycerol-induced acute renal failure. *Kidney Int.* 2006;69(8):1385-92.
- 667 68. Nydam TL, Plenter R, Jain S, Lucia S, and Jani A. Caspase Inhibition During Cold  
668 Storage Improves Graft Function and Histology in a Murine Kidney Transplant Model.  
669 *Transplantation.* 2018;102(9):1487-95.
- 670 69. Zhang X, Zheng X, Sun H, Feng B, Chen G, Vladau C, et al. Prevention of renal  
671 ischemic injury by silencing the expression of renal caspase 3 and caspase 8.  
672 *Transplantation.* 2006;82(12):1728-32.
- 673 70. Yang C, Zhao T, Zhao Z, Jia Y, Li L, Zhang Y, et al. Serum-stabilized naked caspase-3  
674 siRNA protects autotransplant kidneys in a porcine model. *Mol Ther.* 2014;22(10):1817-  
675 28.
- 676 71. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, et al. Clinical  
677 Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury.  
678 *American journal of transplantation : official journal of the American Society of*  
679 *Transplantation and the American Society of Transplant Surgeons.* 2007;7(1):218-25.
- 680

681

682 **Figure legends:**

683

684 **Figure 1: Caspase-3 deficient mice show reduced long-term tubular and microvascular injury**  
685 **after renal IRI and better-preserved renal function after severe IRI.** (A) Serum creatinine levels in  
686 wild-type and caspase-3<sup>-/-</sup> (KO) mice at baseline (pre-operation), and 1, 2, 7 and 21 days post 30  
687 min and 60 min IRI. (B) Left panel: Representative haematoxylin and eosin (H&E) stained renal  
688 sections showing tubular injury from wild-type and caspase-3<sup>-/-</sup> mice at 21 days post 60 min IRI.  
689 Black arrow: polynuclear neutrophil; green arrow: cast formation; blue arrow: tubular dilation  
690 (magnification 200X and 400X). Right panel: Mean tubular injury scores of ten randomly chosen  
691 high-power fields in mice renal cortical sections at pre-operation and post-IRI at 1, 2, 7 and 21 days  
692 from wild-type and caspase-3<sup>-/-</sup> mice that underwent 30 min and 60 min IRI. (C) Left panel:  
693 Representative H&E-stained murine renal sections showing rouleaux formation at 21 days post 60  
694 min IRI (magnification 200X and 400 X). Red arrow: rouleaux formation (vascular congestion). Right  
695 panel: Quantification of rouleaux formation in H&E-stained renal cortical sections at pre-operation  
696 and post-IRI at 1, 2, 7 and 21 days from wild-type and caspase-3<sup>-/-</sup> mice that underwent 30 min and  
697 60 min IRI. Scale bar = 50 µm (magnification 200X), scale bar = 100 µm (magnification 400X).  
698 Values are mean ± SEM. \* P < 0.05 between group.

699 **Figure 2: Caspase-3 deficiency preserves the integrity of peritubular capillaries post-IRI.** (A)  
700 Upper panel: Representative images of MECA-32 immunohistochemistry in the whole kidney and  
701 renal cortical-medullary junction from wild-type and caspase-3<sup>-/-</sup> mice that underwent 60 min IRI and  
702 were sacrificed 21 days post-IRI or sham-operation (magnification 200X). Lower panel:  
703 Quantification of MECA-32 positive peritubular capillary (PTC) in murine renal cortical-medullary  
704 junction sections at 21 days post 30 min and 60 min IRI or sham group. (B) Left panel:  
705 Representative images of MECA-32 immunohistochemistry staining within glomeruli from wild-type  
706 and caspase-3<sup>-/-</sup> mice that underwent 60 min IRI and were sacrificed 21 days post-IRI or sham-  
707 operation (magnification 200X). Right panel: Quantification of MECA-32 positive glomeruli in murine  
708 renal sections at 21 days post 30 min and 60 min IRI or sham group. Scale bar = 50 µm. Values are  
709 mean ± SEM. \* P < 0.05 between group. # P < 0.05 compared to WT or KO SHAM.



710 **Figure 3: Caspase-3 deficiency prevents endothelial apoptosis after severe IRI.** (A-C):  
711 Representative electron micrographs of PTC from wild-type mice that underwent 60 min IRI and  
712 sacrificed 21 days post-IRI. (D-F): Representative EM images of PTC from caspase-3<sup>-/-</sup> mice that  
713 underwent 60 min IRI and sacrificed 21 days post-IRI. Blue arrow: apoptotic bodies; red arrow:  
714 apoptotic exosome-like vesicles; yellow arrow: nuclear condensation; black arrow: capillary  
715 endothelium fenestration; scale bar = 2 μm.

716 **Figure 4: Caspase-3 deficiency prevents microvascular rarefaction of peritubular capillaries**  
717 **in mild and severe forms of IRI.** (A) Representative microCT 3D reconstruction images of whole  
718 renal microvasculature from wild-type and caspase-3<sup>-/-</sup> mice that underwent 30 min and 60 min IRI  
719 and were sacrificed at 21 days post-IRI or pre-operation. Terminal capillaries in the kidney are  
720 labeled as green dots, scale bar = 1000 μm. (B) Quantification of total renal blood vessel volume  
721 from wild-type and caspase-3<sup>-/-</sup> mice at 21 days post 30 min and 60 min IRI or sham-operation. (C)  
722 Quantification of renal terminal capillary number from wild-type and caspase-3<sup>-/-</sup> mice at 21 days  
723 post 30 min and 60 min IRI or sham-operation. Values are mean ± SEM. \* P < 0.05 between group.  
724 # P < 0.05 compared to WT or KO SHAM.

725 **Figure 5: Caspase-3 deficient mice show reduced long-term endothelial permeability**  
726 **disturbances after mild and severe IRI.** (A) Representative intra-vital live images showing renal  
727 microvascular endothelial permeability and perfusion from wild-type and caspase-3<sup>-/-</sup> mice that  
728 underwent 30 min and 60 min IRI and were sacrificed 21 days post-IRI. Green channel: fluorescein  
729 isothiocyanate-labeled dextran (2000 kDa); red channel: Evans Blue dye; white arrow: peritubular  
730 capillary (PTC) permeability depicted by Evans Blue leaking, scale bar = 50 μm. (B) Quantification of  
731 the length of non-perfused renal PTC from wild-type and caspase-3<sup>-/-</sup> mice at 21 days post 30 min  
732 and 60 min IRI. (C) Quantification of renal PTC perfusion ratio from wild-type and caspase-3<sup>-/-</sup> mice  
733 at 21 days post 30 min and 60 min IRI. (D) Left panel: Representative images of a retrieved ischemic  
734 kidney after Evans Blue perfusion from wild-type and caspase-3<sup>-/-</sup> mice that underwent 60 min IRI  
735 and were sacrificed 21 days post-IRI. Right panel: Quantification of renal *ex vivo* Evans Blue  
736 extravasation volume from wild-type and caspase-3<sup>-/-</sup> mice at 21 days post 30 min and 60 min IRI or

737 sham-operation. Values are mean  $\pm$  SEM. \*  $P < 0.05$  between group. #  $P < 0.05$  compared to WT or  
738 KO SHAM.

739 **Figure 6: Caspase-3 deficiency attenuates long-term collagen deposition in peritubular**  
740 **capillary after mild and severe IRI.** (A) Left panel: Representative images of Sirius Red staining  
741 within peritubular capillary (PTC) in renal cortical-medullary junction sections from wild-type and  
742 caspase-3<sup>-/-</sup> mice that underwent 60 min IRI and were sacrificed 21 days post-IRI, or sham-operation.  
743 Arrowheads show collagen deposition in PTC (magnification 200X), scale bar = 50  $\mu$ m. Right panel:  
744 Quantification of Sirius Red positive area within PTC in murine renal cortical-medullary junction  
745 sections at pre-operation, sham-operation, and 21 days post 30 min and 60 min IRI. (B) Left panel:  
746 Representative Sirius Red positive glomeruli in renal cortical section from wild-type and caspase-3<sup>-/-</sup>  
747 mice that underwent 60 min IRI and were sacrificed 21 days post-IRI, or sham-operation  
748 (magnification 200X), scale bar = 50  $\mu$ m. Right panel: Quantification of Sirius Red positive glomeruli  
749 in renal cortical section from wild-type and caspase-3<sup>-/-</sup> mice at pre-operation, sham-operation and  
750 21 days post 30 min and 60 min IRI. (C) Representative electron micrographs of collagen deposition  
751 in PTC from wild-type and caspase-3<sup>-/-</sup> mice that underwent 60 min IRI and were sacrificed 21 days  
752 post-IRI (magnification 3200X), arrowhead: collagen deposition in PTC, scale bar = 2  $\mu$ m. Values are  
753 mean  $\pm$  SEM.\*  $P < 0.05$  between group. #  $P < 0.05$  compared to WT or KO SHAM.

754 **Figure 7: Caspase-3 deficient mice show reduced long-term renal fibrosis after mild and**  
755 **severe IRI.** (A) Upper panel: Representative  $\alpha$ -SMA immunohistochemistry staining in whole murine  
756 kidney section 21 days after 60 min IRI. Middle panel: Representative  $\alpha$ -SMA immunohistochemistry  
757 staining within peritubular capillary (PTC) in renal cortical section at day 21 after 60 min IRI  
758 (magnification 200X), scale bar = 50  $\mu$ m. Lower panel: Representative  $\alpha$ -SMA  
759 immunohistochemistry staining within glomeruli in renal cortical section at day 21 after 60 min IRI  
760 (magnification 200X), scale bar = 50  $\mu$ m. (B) Quantification of  $\alpha$ -SMA positive PTC in renal cortical  
761 sections from wild-type and caspase-3<sup>-/-</sup> mice at 21 days post 30 min and 60 min IRI. (C)  
762 Quantification of  $\alpha$ -SMA positive glomeruli in renal cortical sections from wild-type and caspase-3<sup>-/-</sup>  
763 mice at 21 days post 30 min and 60 min IRI. (D) Quantification of  $\alpha$ -SMA positive cells in

764 macrovessels in renal sections from wild-type and caspase-3<sup>-/-</sup> mice at 21 days post 30 min and 60  
765 min IRI. Values are mean ± SEM. \* P < 0.05 between group. # P < 0.05 compared to WT or KO  
766 SHAM.

767 **Figure 8 : Impact of caspase-3 on microvascular endothelial injury and renal fibrosis and**  
768 **dysfunction post-IRI.** Microvascular injury induced by renal IRI increases disturbances in  
769 microvascular permeability and microvascular rarefaction. It promotes secondary tubular injury,  
770 collagen deposition and myofibroblast differentiation, which result in long-term renal dysfunction and  
771 renal interstitial fibrosis. Caspase-3 is a pivotal regulator of renal dysfunction as its deficiency largely  
772 prevents the above pathophysiological changes.

773

774

775

776

777

778 **Supplementary Figure legends:**

779

780 **Supplementary Figure 1: Caspase-3 deficiency ameliorates long-term renal tubular injury and**  
781 **microvascular injury after mild IRI.** (A) Tubular injury in representative renal sections from wild-  
782 type and caspase-3<sup>-/-</sup> mice at day 21 post 30 min of IRI and stained with haematoxylin and eosin  
783 (H&E). (magnifications 200X and 400X). (B) Representative H&E-stained renal sections showing  
784 rouleaux formation at day 21 post 30 min of IRI (magnifications 200X and 400X). Scale bar = 50 µm  
785 (magnification 200X), scale bar = 100 µm (magnification 400X).

786 **Supplementary Figure 2: Description of multiple morphologies in MECA-32**  
787 **immunohistochemistry staining in peritubular capillaries (PTCs).** Upper panel: Representative  
788 images of MECA-32 immunohistochemistry (magnification 200X), scale bar = 50 µm. Lower panel: a:  
789 Capillary lumen is clearly stained; b: Capillary lumen is weakly stained; c: Capillary lumen is weakly  
790 stained, but the structural outline is visible; d: Smaller positive capillary; e: Capillary lumen is  
791 invisible, but the longitudinal axis is visible; f: Capillary lumen is visible, with cellular circulation inside.

792 **Supplementary Figure 3: Caspase-3 deficiency prevents endothelial apoptosis post severe IRI.**  
793 (A) Representative images of caspase-3 immunohistochemistry from wild-type and caspase-3<sup>-/-</sup> mice  
794 that underwent 60 min IRI (magnification 200X). Arrow: caspase-3 positive endothelial-like cells. (B)  
795 Quantification of caspase-3 positive endothelial-like cells in PTC from wild-type mice and caspase-3<sup>-/-</sup>  
796 mice at 21 days post 60 min IRI. Scale bar = 50 µm. Values are mean ± SEM.\* P < 0.05.

797 **Supplementary Figure 4: Caspase-3 deficiency does not modulate long term renal**  
798 **glomerulosclerosis post severe IRI.** (A) Representative photos of silver-stained renal sections  
799 showing glomerulosclerosis at day 21 post 60 min of IRI (magnification 200X). (B) Quantification of  
800 glomerulosclerosis in murine renal glomeruli at day 21 post 60 min of IRI, scale bar = 50 µm. Values  
801 are mean ± SEM.\* P < 0.05.

802 **Supplementary Figure 5: Intra-vital images of renal capillary perfusion in sham-operated mice.**  
803 (A) Upper panel: intra-vital images of peritubular capillaries prior to Evans Blue injection and 30  
804 seconds, 5 minutes, and 15 minutes post-injection in sham-operated WT mice. (B) Lower panel:

805 intra-vital images of peritubular capillaries prior to Evans Blue injection and 30 seconds, 5 minutes,  
806 and 15 minutes post-injection in sham-operated caspase-3<sup>-/-</sup> mice. Scale bar = 50 μm.

807 **Supplementary Figure 6: Definitions of different types of renal capillaries in intra-vital live**  
808 **confocal imaging.** (A) Definition and example of capillary segments quantification. (B) Definitions  
809 and examples of multiple types of renal peritubular capillaries (PTCs) post-IRI.

810 **Supplementary Figure 7: Caspase-3 deficiency ameliorates tubular hypoxia after AKI.** (A)  
811 Quantification of HIF-1α in murine renal cortical section at day 21 post 30 min and 60 min of IRI. (B)  
812 Quantification of HIF-1α at the cortical-medullary junction at day 21 post 30 min and 60 min of IRI.  
813 Values are mean ± SEM.\* P < 0.05.

814

815 **Video 1: Z stack image showing PTC leaking in WT mice at day 21 post IR for 60 min (zoom 3).**  
816 Red area: Evans Blue leakage. Yellow/Green: Capillary. Blue: Tubules.

817 **Video 2: Z stack image showing PTC leaking in caspase-3<sup>-/-</sup> mice at day 21 post IR for 60 min**  
818 **(zoom 3).** Red area: Evans Blue leakage. Yellow/Green: Capillary. Blue: Tubules.

819 **Video 3: Live imaging showing PTC perfusion in WT mice at day 21 post IR for 60 min**  
820 **(zoom1-zoom3).** Red area: Evans Blue leakage . Yellow/Green: Capillary. Blue: Tubules.

821 **Video 4: Live imaging showing PTC perfusion in caspase-3<sup>-/-</sup> mice at day 21 post IR for 60 min**  
822 **(zoom1-zoom3).** Red area: Evans Blue leakage. Yellow/Green: Capillary. Blue: Tubules.

823 **Video 5: Live imaging showing glomerular leakage in WT mice at day 21 post IR for 30 min**  
824 **(zoom 1).** Red area: Evans Blue leakage. Yellow/Green: Capillary. Blue: Tubules. Star: Glomerular  
825 leakage of Evans Blue in tubular lumen.

826 **Video 6: Live imaging showing PTC leakage and glomerular leakage in caspase-3<sup>-/-</sup> mice at**  
827 **day 21 post IR for 30 min (zoom 1).** Red area: Evans Blue leakage. Yellow/Green: Capillary. Blue:  
828 Tubules. Arrow: PTC leakage of Evans Blue. Star: Glomerular leakage of Evans Blue in tubular  
829 lumen.

830 **Video 7: Live imaging showing PTC leaking process (zoom 1).** Red area: Evans Blue leakage.  
831 Yellow/Green: Capillary. Blue: Tubules. Arrow: PTC leakage of Evans Blue.

832 **Video 8: Live imaging showing glomerular leaking process (zoom 3).** Red area: Evans Blue  
833 leakage. Yellow/Green: Capillary. Blue: Tubules. Star: Glomerular leakage of Evans Blue in tubular  
834 lumen.

835 **Video 9: Live imaging showing different renal PTCs definitions post-IRI (zoom 3).** Arrowhead:  
836 non-perfused PTC; Arrow: perfused PTC without circulation; Star: PTC with normal circulation.

837

838

839

840

841

842

843

844

845

846






Figure 1: Caspase-3 deficient mice show reduced long-term tubular and microvascular injury after renal IRI and better-preserved renal function after severe IRI.

**A**



**B**





Figure 2: Caspase-3 deficiency preserves the integrity of peritubular capillaries post-IRI.  
 Downloaded from journals.physiology.org/journal/aprenal at Hotel-Dieu Du CHUM (206.167.168.129) on August 3, 2021.






Figure 3: Caspase-3 deficiency prevents endothelial apoptosis post severe IRI.




Figure 4: Caspase-3 deficiency prevents microvascular rarefaction of terminal capillary in mild and severe forms of IRI.




Figure 5: Caspase-3 deficient mice show reduced long-term endothelial permeability disturbances after mild and severe IRI.







**A****B****C**

Figure 6: Caspase-3 deficiency attenuates long-term collagen deposition in peritubular capillary after mild and severe IRI.




Figure 7: Caspase-3 deficient mice show reduced long-term renal fibrosis after mild and severe IRI.







Figure 8: Impact of caspase-3 on microvascular endothelial injury and renal fibrosis and dysfunction post IRI.

# Caspase-3 dependent peritubular capillary dysfunction is pivotal for transition from acute to chronic kidney disease after acute ischemia-reperfusion injury

## METHODS

Renal ischemia-reperfusion model





WT(C57/Bl6) mice  
Caspase-3 general KO mice



## OUTCOME

Caspase-3 deficiency ameliorates renal microvascular dysfunction and fibrosis post ischemia-reperfusion injury (IRI)

Caspase-3  
regulation



CKD  
transition

Progressive  
loss of renal  
function

## CONCLUSION

The severity of PTC disturbances after ischemia-reperfusion injury is a major predictor of acute kidney injury (AKI) to chronic kidney disease (CKD) transition. Caspase-3 is a central regulator of microvascular rarefaction, fibrogenesis, and long-term renal function.